BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 24571714)

  • 1. Assessing tissue damage in multiple sclerosis: a biomarker approach.
    Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
    Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
    Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
    Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.
    Takano R; Misu T; Takahashi T; Sato S; Fujihara K; Itoyama Y
    Neurology; 2010 Jul; 75(3):208-16. PubMed ID: 20644148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
    J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement.
    Trysberg E; Nylen K; Rosengren LE; Tarkowski A
    Arthritis Rheum; 2003 Oct; 48(10):2881-7. PubMed ID: 14558094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
    Misu T; Fujihara K; Kakita A; Konno H; Nakamura M; Watanabe S; Takahashi T; Nakashima I; Takahashi H; Itoyama Y
    Brain; 2007 May; 130(Pt 5):1224-34. PubMed ID: 17405762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
    Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
    Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.
    Malmeström C; Haghighi S; Rosengren L; Andersen O; Lycke J
    Neurology; 2003 Dec; 61(12):1720-5. PubMed ID: 14694036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid derived from progressive multiple sclerosis patients promotes neuronal and oligodendroglial differentiation of human neural precursor cells in vitro.
    Cristofanilli M; Cymring B; Lu A; Rosenthal H; Sadiq SA
    Neuroscience; 2013 Oct; 250():614-21. PubMed ID: 23876320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients.
    Sarchielli P; Di Filippo M; Candeliere A; Chiasserini D; Mattioni A; Tenaglia S; Bonucci M; Calabresi P
    J Neuroimmunol; 2007 Aug; 188(1-2):146-58. PubMed ID: 17628700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.